Table 3.
Treatment related adverse events seen in patients receiving at least one M‐PHP procedure
| Adverse event | Any grade N = % | Grade 3‐4 N = % | ||
|---|---|---|---|---|
| Hematological toxicity | ||||
| Anemia | 51 | 100.0% | 15 | 29.4% |
| Neutropenia | 22 | 43.1% | 16 | 31.3% |
| Thrombocytopenia | 50 | 98.0% | 16 | 31.3% |
| Coagulopathic toxicity | ||||
| Hemorrhagic Event | 10 | 19.6% | 2 | 3.9% |
| Thromboembolic Event | 7 | 13.7% | 6 | 11.8% |
| Cardiovascular toxicity | ||||
| Any | 11 | 21.6% | 9 | 17.6% |
| Arrhythmias | 5 | 9.8% | 4 | 7.8% |
| Pulmonary Edema | 3 | 5.9% | 3 | 5.9% |
| Cardiac Ischemia | 5 | 9.8% | 5 | 9.8% |
| Cerebrovascular event | 2 | 3.9% | 0 | 0.0% |
| Late toxicity | ||||
| Fatigue | 17 | 33.3% | 1 | 2.0% |
| Mucositis | 1 | 2.0% | 0 | 0.0% |
| Nausea | 12 | 23.5% | 0 | 0.0% |
| Vomiting | 8 | 15.6% | 0 | 0.0% |
| Epigastric pain | 6 | 11.8% | 0 | 0.0% |
| Transaminitis | 15 | 29.4% | 3 | 5.9% |
| Rash | 1 | 2.0% | 0 | 0.0% |
| Constipation | 2 | 3.9% | 0 | 0.0% |